Medications Contraindicated in Hemophilia
In patients with hemophilia, aspirin and NSAIDs are contraindicated due to their antiplatelet effects and increased risk of gastrointestinal bleeding, and intramuscular injections should be avoided due to bleeding risk. 1
Absolute Contraindications
Antiplatelet and Anti-inflammatory Agents
Aspirin and traditional NSAIDs (tNSAIDs) should not be administered to patients with hemophilia due to their dual mechanism of increasing bleeding risk: platelet inhibition and gastrointestinal mucosal injury. 1
Intramuscular injections are contraindicated in all patients with hemophilia regardless of severity, as they pose significant risk of intramuscular hematoma formation. 1
Specific Hemophilia B Considerations
- Factor IX (FIX) concentrates are contraindicated in patients with hemophilia B who have inhibitors and a documented history of anaphylaxis following previous FIX administration. 1
Conditional Contraindications Requiring Prophylaxis
Antithrombotic Therapy Without Adequate Factor Coverage
In severe hemophilia A or B, antithrombotic medication in any form is not recommended without regular coagulation factor (FVIII or FIX) prophylaxis or emicizumab use. 2
Systemic thrombolysis is not recommended in patients with hemophilia who develop acute ischemic stroke due to unknown efficacy and safety profile. 2
Antithrombotic medications are not recommended in patients with severe hemophilia with noncardioembolic transient ischemic attack without FVIII or FIX prophylaxis. 2
Medications Requiring Extreme Caution
COX-2 Selective Inhibitors
While COX-2 selective NSAIDs may be considered when anti-inflammatory therapy is absolutely necessary, they should only be used at the lowest effective dose for the shortest duration, combined with a proton pump inhibitor, and after testing for and eradicating Helicobacter pylori infection. 3
Regular monitoring of blood pressure and renal function is mandatory during COX-2 inhibitor treatment. 3
Bypassing Agents in Specific Contexts
- Activated prothrombin complex concentrate should not be used concomitantly with emicizumab due to potential thrombotic complications; recombinant FVIIa is preferred in this setting. 4
Outdated Therapies to Avoid
Fresh frozen plasma and cryoprecipitate should not be used for hemophilia treatment, as they have been superseded by safer and more effective factor concentrates. 1
Desmopressin should not be used in cases of hematuria in patients with hemophilia. 1
Common Pitfalls
The most critical error is prescribing antiplatelet or anticoagulant therapy without ensuring adequate hemostatic coverage. Factor VIII or FIX levels must be maintained at 1-5 IU/dL for single antiplatelet therapy and 20 IU/dL for dual antiplatelet therapy when antithrombotic treatment is absolutely necessary. 2
Another common mistake is performing closed casting for fractures in hemophilia patients, which should be avoided due to compartment syndrome risk. 1